Newmeta G16 Injection
L-Alanine 0.466g · L-Arginine 0.489g +26 more
Injections · Prescription medication · Combination
Baxter Korea Co., Ltd.
MFDS item code 201805067 · Approved 2018.12.13
Correction of fluid, electrolyte, and nutritional deficiencies in newborns and children 2 years of age and under
This medication is used to provide necessary fluids, electrolytes, amino acids, and calories for term newborns and children up to 2 years of age who are unable to obtain adequate nutrition orally or via enteral feeding. It assists children in normal growth and maintaining health. By supplying nutrients intravenously, it effectively supplements lacking nutrients. Therefore, using this medication can contribute to improving children's nutritional status and overall health in cases where such nutritional support is needed.
Determine the dose according to the patient's condition, energy expenditure, body weight, age, metabolic capacity, and additional calories or protein supplied orally or via the gastrointestinal tract. Do not exceed the maximum recommended dose. Because the composition of the multi-chamber bag is fixed, it may not meet all of the patient's nutritional requirements at the same time. There may be clinical situations in which the patient requires nutrients in proportions different from the fixed composition. Determine the maximum recommended infusion rate per hour and daily dose according to the components. If any one component is administered at its maximum dose, the maximum daily dose of this medicine has been reached. The maximum recommended infusion rate per hour and daily dose are as follows. Three-chamber admixture (500 mL) Maximum infusion rate (mL/kg/hour) 5.5 Equivalent to: Amino acids (g/kg/hour) 0.14 Glucose (g/kg/hour) 0.85 Lipids (g/kg/hour) 0.17 Maximum infusion volume (mL/kg/day) 96.2 Equivalent to: Amino acids (g/kg/day) 2.5 Glucose (g/kg/day) 14.9 Lipids (g/kg/day) 3.0 Osmolarity (approximately mOsm/L) 1230 Because this undiluted medicine has high osmolarity, it can be administered only through a central vein. However, sufficient dilution of this medicine with water for injection lowers its osmolarity, making peripheral intravenous infusion possible. Gradually increase the infusion rate during the first hour of administration. When discontinuing this medicine, gradually decrease the infusion rate during the 1 hour before stopping the infusion. Adjust the infusion rate taking into account the dose to be administered, daily intake, and infusion time. The same bag should not be infused for more than 24 hours. Cyclic infusions should be managed according to the patient's metabolic tolerance. Parenteral nutrition therapy may be continued for as long as the patient's clinical condition requires. This medicine contains electrolytes. Electrolytes may be supplemented, and vitamins and trace elements may be added, according to the physician's judgment and the patient's clinical needs (see Precautions for Use, “10. Precautions for Administration”).
Caution is necessary when administering this drug to premature and low birth weight infants. These infants have a reduced ability to remove lipids from the blood, which may lead to elevated levels of free fatty acids when this drug is administered intravenously. In cases of premature infants with severe respiratory conditions, the lipid components of this drug may accumulate in the pulmonary vasculature, leading to potentially fatal outcomes, so it is advisable to avoid its use. This drug should not be administered to patients with allergies to eggs, soybeans, peanuts, or congenital amino acid metabolism disorders, or to patients with abnormally high electrolyte levels. Additionally, in newborns aged 28 days or younger, concurrent administration with ceftriaxone is contraindicated, as it poses risks. It is also prohibited in patients with severe hyperglycemia, hyperlipidemia, or severe lipid metabolism disorders. In patients with pulmonary edema or heart failure, administration should be done cautiously while monitoring fluid status closely. Patients with renal failure should also carefully monitor fluid and electrolyte status, and patients with severely impaired liver function should regularly check liver function values during administration. Patients with endocrine and metabolic disorders may experience metabolic anomalies if the nutritional provision is not tailored to the patient's needs or metabolic capacity is insufficiently assessed, so caution is warranted. Allergic reactions may occur during administration of this drug; should symptoms such as fever, rash, or respiratory distress occur, administration should be stopped immediately. Also, because it contains corn-derived glucose, it should be used cautiously in patients allergic to corn. This drug can cause tissue damage and skin necrosis due to extravasation during intravenous administration, so it must be properly diluted and infused through a central vein. Peripheral vein administration can be risky. During administration, blood glucose, electrolytes, liver and kidney function, coagulation status, etc. should be regularly tested in order to detect abnormalities early. In particular, magnesium levels should be periodically checked to prevent hypermagnesemia, and the infusion rate should be adjusted or stopped if necessary. In case of overdose, symptoms such as vomiting, tremors, electrolyte abnormalities, and fluid overload may occur, so administration should be stopped immediately and appropriate treatment should be provided. There is no antidote for overdose of this drug, so symptomatic supportive treatment is necessary. This drug may interact with other calcium-containing preparations or specific medications, so it is essential to consult healthcare providers before administration. Safety data on pregnant or lactating women is insufficient, thus risks and benefits should be carefully evaluated when using it. Finally, this drug must be used immediately after opening, and storage or reuse should be avoided. Additionally, aseptic techniques and catheter management should be observed to prevent infections during administration.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly sealed container, maintaining a temperature between 1 and 25 degrees Celsius. It is also important not to freeze the drug.
The amino acid solution and sugar solution are colorless to pale yellow transparent liquids, while the lipid solution is a homogeneous cloudy liquid separated into three spaces within a single transparent plastic bag by two partitions.
500 ml (Amino Acid Solution 221ml, Sugar Solution 155ml, Lipid Solution 124ml) / Bag
Even with the same ingredient, strength, dosage form and how it is taken can differ.
L-Alanine 0.466g · L-Arginine 0.489g +26 more
Injections · Prescription medication · Combination
Baxter Korea Co., Ltd.
L-Alanine 0.466g · L-Arginine 0.489g +26 more
Injections · Prescription medication · Combination
Baxter Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.